NextCure, Inc.
NXTC
$0.40
$0.01423.68%
| Weiss Ratings | NXTC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | NXTC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | NXTC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.47 | |||
| Price History | NXTC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -19.84% | |||
| 30-Day Total Return | -47.37% | |||
| 60-Day Total Return | -49.94% | |||
| 90-Day Total Return | -66.67% | |||
| Year to Date Total Return | -51.34% | |||
| 1-Year Total Return | -80.49% | |||
| 2-Year Total Return | -74.36% | |||
| 3-Year Total Return | -92.41% | |||
| 5-Year Total Return | -98.89% | |||
| 52-Week High % Change | -82.70% | |||
| 52-Week Low % Change | 9.66% | |||
| Price | NXTC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.23 | |||
| 52-Week Low Price | $0.35 | |||
| 52-Week Low Price (Date) | Apr 02, 2025 | |||
| 52-Week High Price (Date) | Apr 08, 2024 | |||
| Valuation | NXTC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 10.80M | |||
| Enterprise Value | -51.87M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.99 | |||
| Earnings Per Share Growth | -11.66% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.17 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.40 | |||
| Enterprise Value/EBITDA (TTM) | 0.95 | |||
| Enterprise Value/EBIT | 0.91 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | NXTC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 28.01M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NXTC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 240 399 4900 | |||
| Address | 9000 Virginia Manor Road Beltsville, MD 20705 | |||
| Website | www.nextcure.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | NXTC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | NXTC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -34.23% | |||
| Return on Equity | -- | |||
| Income Statement | NXTC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -54.34M | |||
| EBIT (TTM) | -57.21M | |||
| Net Income (TTM) | -55.65M | |||
| Net Income Avl. to Common (TTM) | -55.65M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 19.80% | |||
| EPS Diluted (TTM) | -1.99 | |||
| EPS Diluted Growth (Q YOY) | 20.10% | |||
| Balance Sheet | NXTC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 68.62M | |||
| Cash Per Share (Q) | $2.45 | |||
| Total Current Assets (Q) | 71.81M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 65.47M | |||
| Current Ratio (Q) | 7.500 | |||
| Book Value Per Share (Q) | $2.34 | |||
| Total Assets (Q) | 80.86M | |||
| Total Current Liabilities (Q) | 9.57M | |||
| Total Debt (Q) | 5.95M | |||
| Total Liabilities (Q) | 15.39M | |||
| Total Common Equity (Q) | 65.47M | |||
| Cash Flow | NXTC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 55.31M | |||
| Cash from Financing (TTM) | 144.00K | |||
| Net Change in Cash (TTM) | 14.65M | |||
| Levered Free Cash Flow (TTM) | -23.24M | |||
| Cash from Operations (TTM) | -40.81M | |||
